NasdaqGS - Delayed Quote USD

Lifecore Biomedical, Inc. (LFCR)

6.89
+0.18
+(2.76%)
At close: May 16 at 4:00:02 PM EDT
6.89
0.00
(0.00%)
After hours: May 16 at 4:05:08 PM EDT
Loading Chart for LFCR
  • Previous Close 6.71
  • Open 6.71
  • Bid 4.93 x 200
  • Ask 8.61 x 200
  • Day's Range 6.67 - 6.91
  • 52 Week Range 3.68 - 7.99
  • Volume 183,659
  • Avg. Volume 238,646
  • Market Cap (intraday) 255.289M
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) --
  • EPS (TTM) -1.47
  • Earnings Date Apr 3, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.00

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

www.lifecore.com

524

Full Time Employees

May 26

Fiscal Year Ends

Recent News: LFCR

View More

Performance Overview: LFCR

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LFCR
7.20%
S&P 500 (^GSPC)
1.30%

1-Year Return

LFCR
19.50%
S&P 500 (^GSPC)
12.48%

3-Year Return

LFCR
23.90%
S&P 500 (^GSPC)
48.66%

5-Year Return

LFCR
30.07%
S&P 500 (^GSPC)
108.07%

Compare To: LFCR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LFCR

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    255.29M

  • Enterprise Value

    380.21M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.84

  • Price/Book (mrq)

    114.53

  • Enterprise Value/Revenue

    2.92

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -34.27%

  • Return on Assets (ttm)

    -3.11%

  • Return on Equity (ttm)

    -83.58%

  • Revenue (ttm)

    130.31M

  • Net Income Avi to Common (ttm)

    -49.4M

  • Diluted EPS (ttm)

    -1.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.42M

  • Total Debt/Equity (mrq)

    274.83%

  • Levered Free Cash Flow (ttm)

    -27.28M

Research Analysis: LFCR

View More

Company Insights: LFCR

Research Reports: LFCR

View More

People Also Watch